Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Ventripoint Announces Appointment of Chief Finance Officer

V.VPT

(TheNewswire)

Ventripoint Diagnostics Ltd.

Toronto, Ontario - TheNewswire - October 3, 2023 - Ventripoint Diagnostics Ltd. ("Ventripoint"orthe"Company"),(TSXV:VPT)(OTC:VPTDF)is pleased to announce the appointment of Mr. Jimmy Jeon as Chief Financial Officer (“CFO”) of the Company. Mr. Jeon replaces Mr. Victor Hugo, who has served as CFO since June 2020. The Company wishes to thank Mr. Hugo for fulfilling that role and to express its appreciation for his service.

Mr. Jeon currently works as a Senior Financial Analysist at Marrelli Support Services Inc. where he provides CFO, accounting, regulatory compliance, and management advisory services to numerous public trading companies on the TSX, TSX Venture Exchange and other Canadian and U.S. exchanges. Mr. Jeon is a CPA and holds a Bachelor of Business Administration and Graduate Diploma in Accounting from Wilfrid Laurier University. Mr. Jeon has over 6 years’ experience in various sectors, with responsibility for accounting, budgeting, financial reporting and disclosures.

AboutVentripointDiagnosticsLtd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Jonathan Robinson

JRobinson@oakhillfinancial.ca

(416)-669-1001

Dr. Alvira Macanovic

President & CEO

amacanovic@ventripoint.com

(416) 848-4156

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that termisdefinedinpoliciesoftheTSXVentureExchange)acceptsresponsibilityfor the adequacy or accuracy of this release.

Copyright (c) 2023 TheNewswire - All rights reserved.